BML-190
Based on 1 Customer Validation
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.53%
- CAS No.: 2854-32-2
- Formule: C23H23ClN2O4
- Masse moléculaire:426.89
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Activité biologique
Chemical Information
-
CAS No. 2854-32-2
-
Appearance Solid
-
Masse moléculaire 426.89
-
Formule C23H23ClN2O4
-
Color Light yellow to yellow
-
SMILES
CC(N1C(C2=CC=C(Cl)C=C2)=O)=C(CC(N3CCOCC3)=O)C4=C1C=CC(OC)=C4
-
Synonyms
Indomethacin morpholinylamide; IMMA
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
DMSO : 50 mg/mL (117.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Klegeris, Andis; Bissonnette, Christopher J.; McGeer, Patrick L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology (2003), 139(4), 775-786. [Content Brief]
[3]. New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003 Feb 11;536(1-3):157-60. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3425 mL | 11.7126 mL | 23.4252 mL | 58.5631 mL |
| 5 mM | 0.4685 mL | 2.3425 mL | 4.6850 mL | 11.7126 mL | |
| 10 mM | 0.2343 mL | 1.1713 mL | 2.3425 mL | 5.8563 mL | |
| 15 mM | 0.1562 mL | 0.7808 mL | 1.5617 mL | 3.9042 mL | |
| 20 mM | 0.1171 mL | 0.5856 mL | 1.1713 mL | 2.9282 mL | |
| 25 mM | 0.0937 mL | 0.4685 mL | 0.9370 mL | 2.3425 mL | |
| 30 mM | 0.0781 mL | 0.3904 mL | 0.7808 mL | 1.9521 mL | |
| 40 mM | 0.0586 mL | 0.2928 mL | 0.5856 mL | 1.4641 mL | |
| 50 mM | 0.0469 mL | 0.2343 mL | 0.4685 mL | 1.1713 mL | |
| 60 mM | 0.0390 mL | 0.1952 mL | 0.3904 mL | 0.9761 mL | |
| 80 mM | 0.0293 mL | 0.1464 mL | 0.2928 mL | 0.7320 mL | |
| 100 mM | 0.0234 mL | 0.1171 mL | 0.2343 mL | 0.5856 mL |